Glen Eagle Advisors’s ClearPoint Neuro CLPT Stock Holding History

Glen Eagle Advisors’s Portfolio CLPT Stock Details CLPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$455	Hold	50	–	–	﹤0.01%	973
2025 Q4	$684	Hold	50	–	–	﹤0.01%	987
2025 Q3	$1.09K	Hold	50	–	–	﹤0.01%	989
2025 Q2	$597	Hold	50	–	–	﹤0.01%	971
2025 Q1	$595	Hold	50	–	–	﹤0.01%	986
2024 Q4	$769	Hold	50	–	–	﹤0.01%	996
2024 Q3	$561	Hold	50	–	–	﹤0.01%	1062
2024 Q2	$270	Hold	50	–	–	﹤0.01%	1092
2024 Q1	$340	Hold	50	–	–	﹤0.01%	1043
2023 Q4	$340	Hold	50	–	–	﹤0.01%	985
2023 Q3	$251	Hold	50	–	–	﹤0.01%	988
2023 Q2	$362	Hold	50	–	–	﹤0.01%	1018
2023 Q1	$422	Hold	50	–	–	﹤0.01%	1013
2022 Q4	$424	Hold	50	–	–	﹤0.01%	1093
2022 Q3	$518	Hold	50	–	–	﹤0.01%	1019
2022 Q2	$653	Hold	50	–	–	﹤0.01%	926
2022 Q1	$521	Hold	50	–	–	﹤0.01%	902
2021 Q4	$561	Hold	50	–	–	﹤0.01%	887
2021 Q3	$888	Buy	+50	New	+$938	﹤0.01%	989

Other funds holding CLPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MCO

MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Lane Generational Dover, Massachusetts $126M AUM 53.89% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

Glen Eagle Advisors's CLPT Position: Q1 2026 in Review

Glen Eagle Advisors held its ClearPoint Neuro (CLPT) position steady in Q1 2026 at 50 shares worth $455. The position accounts for ﹤0.01% of the portfolio, ranked #973.

Glen Eagle Advisors first reported a position in CLPT in Q3 2021 and has held it in 19 quarters since. The position peaked at $1.09K in Q3 2025. 118 funds tracked by Wall St. Rank hold CLPT as of Q1 2026.

Glen Eagle Advisors held 50 shares of ClearPoint Neuro worth $455 as of Q1 2026.
Glen Eagle Advisors left its ClearPoint Neuro share count unchanged in Q1 2026.
ClearPoint Neuro made up ﹤0.01% of Glen Eagle Advisors's portfolio in Q1 2026, its #973 holding.
Glen Eagle Advisors first reported a position in ClearPoint Neuro in Q3 2021 and has held it in 19 quarters since.
Glen Eagle Advisors's ClearPoint Neuro position peaked at $1.09K in Q3 2025.
118 funds tracked by Wall St. Rank held ClearPoint Neuro as of Q1 2026.

Based on Glen Eagle Advisors's 13F filing for Q1 2026, filed 15 May 2026.